Savara

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The firm's lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical

Savara to Present at Oppenheimer's 32nd Annual Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on January 10, 2022 on Savara's website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days. About Savara Savara is a

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference: A pre-recorded webcast of the presentation will be available beginning at 10:00 AM ET / 7:00 AM PT on November 22, 2021. Evercore ISI 4th Annual HealthCONx Virtual Conference: A live webcast of a fireside c

Savara to Participate in Two Upcoming Investor Healthcare Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business update. “The team is focused and driving hard on advancing the pivotal Phase 3 IMPALA 2 trial,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “Given that an increasing number of sites are actively screening and enrolling patients, and we c

Savara Reports Third Quarter 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021. A pre-recorded, on-demand webcast of Savara's presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET. Additionally, a replay of the pr

Savara to Present at the Jefferies London Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the Inaugural Piper Sandler Lung Day on Friday, October 15, 2021 at 10:30 am ET / 7:30 am PT. Following the event, a replay of the webcast will be available through the Investors page of Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archiv

Savara to Present at the Inaugural Piper Sandler Lung Day

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On September 2, 2021, the Compensation Committee of Savara's Board of Directors granted inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 200,000 shares of the Company's common stock and restricted

Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter ending June 30, 2021 and provided a business update. “Over the last 9 months we streamlined our portfolio, reduced and restructured the organization, and significantly strengthened the balance sheet so that we could focus solely on advancing the pivotal Phase 3 IMPALA 2 clinical trial,” said Matt Paul

Savara Reports Second Quarter 2021 Financial Results and Provides Business Update

Document Security Systems

Galecto

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can make huge margins of return out of these stocks after the market has reappraised the share prices to near or above the liquidation value.

3 Net Current Asset Value Stock Picks

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo. Molgramostim is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial is expected to be conduct

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Implied Volatility Surging for Savara (SVRA) Stock Options

Savara failed a key phase 3 trial in aPAP.

Savara: They Failed Once, But They Are Trying Again

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at le

Savara to Present at the Jefferies Virtual Healthcare Conference

Infinity Pharma

CASI Pharmaceuticals

IsoRay

PDS Biotechnology Corporation

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's web

Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending March 31, 2021 and provided a business update. “We made considerable progress in the first quarter of the year,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “This includes the strategic decision to wind down two pipeline programs, enabling us to focus solely on advancing our lead

Savara Reports First Quarter 2021 Financial Results and Provides Business Update

Evogene

PAVmed

Synlogic

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%

180 Life Sciences 

Citius Pharmaceuticals

Jaguar Health

Ocugen, Inc.

Timber Pharmaceuticals

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

RF Industries

Geely Automobile Holdings Ltd

While penny stocks are always incredibly risky ventures, these publicly traded companies offer interesting catalysts to consider. The post 7 Penny Stocks with Interesting Catalysts appeared first on InvestorPlace.

7 Penny Stocks with Interesting Catalysts

Lipocine

OrganiGram Holdings Inc.

SNDL Inc.

Liquid Media Group Ltd

Zomedica

Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.

7 Reddit Penny Stocks to Keep Your Eye on for Big Movement

New Age Beverages

FinVolution Group

Strongbridge Biopharma

5 Stocks to Buy Under $10 With Explosive Upside Potential

Marathon Digital Holdings

TherapeuticsMD

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

7 Reddit Penny Stocks Seeing the Most Chatter Today

Do Options Traders Know Something About Savara (SVRA) Stock We Don't?

The stock price of Savara Inc (NASDAQ: SVRA) is trading at above 10% pre-market. This is why it happened.

SVRA Stock Price Increases Over 10% Pre-Market: Why It Happened

News for Savara Stock (SVRA)